Skip to main content
S&P 5007,718.94-1.11%DOW51,621.48-0.09%NASDAQ26,692.87-1.88%BTC$81,676.00-1.81%ETH$2,422.11-3.07%GOLD$4,134.80+0.65%OIL$94.81-0.29%
Smart Investors Daily
SID Premium
Bio-Rad Laboratories, Inc. logo

NYSE · BIO

Bio-Rad Laboratories, Inc.

Healthcare · Medical - Devices

$363.73

Down-$1.30 (-0.36%)

Updated Oct 15, 2026, 12:09 AM

SID Score

5.7/10

Composite research score

Smart Money

58/100

Neutral

Market cap
8.47B
P/E ratio
-12.51
Dividend yield
0.00%
52-week range
$236.73 – $396.23
Volume
132.59K
Avg. volume
214.04K

Price performance · BIO

BIO price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 13, 2026

BIO closed at $363.73 after 20 trading sessions, down 4.04% for the selected period.

Last close
$363.73
Period change
-4.04%
Period low
$355.57
Period high
$387.54
Daily close
View OHLC price history
BIO OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 13, 2026$369.00$369.43$358.425$363.73132.59K
Oct 12, 2026$369.85$369.85$359.41$364.42181.2K
Oct 9, 2026$364.32$368.6699$361.32$366.16138.98K
Oct 8, 2026$371.99$372.59$353.97$360.40312.02K
Oct 7, 2026$373.16$374.60$363.98$367.92251.9K
Oct 6, 2026$383.38$390.00$367.49$368.83162.54K
Oct 5, 2026$368.07$381.78$363.9601$379.82279.4K
Oct 2, 2026$357.28$369.40$357.28$369.14223.65K
Oct 1, 2026$373.87$379.6665$353.30$355.57264.58K
Sep 30, 2026$377.61$380.88$374.02$377.71228.59K
Sep 29, 2026$377.73$381.56$374.785$379.55261.68K
Sep 28, 2026$376.98$383.95$373.18$377.69272.64K
Sep 25, 2026$384.14$387.00$376.4266$381.00253.59K
Sep 24, 2026$377.73$389.38$376.18$387.54374.18K
Sep 23, 2026$379.27$382.85$374.77$378.88177.21K
Sep 22, 2026$377.53$383.25$374.01$379.57374.68K
Sep 21, 2026$381.58$381.58$373.47$377.33311.47K
Sep 18, 2026$383.05$383.05$374.805$376.41324.35K
Sep 17, 2026$384.23$385.71$377.69$382.41204.96K
Sep 16, 2026$378.25$385.325$375.00$379.03262.41K

Latest BIO news

The latest Smart Investors Daily articles mentioning BIO.

Stock researchCompany · Overview

BIO research

Overview

Company profile and research snapshot.

Company profile

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$340.00
Implied upside
—
Analysts
—
BIO recent ratings
DateFirmRatingTarget
Aug 7, 2026RBC CapitalOutperform—
Aug 5, 2026Wells FargoEqual-Weight—
Aug 5, 2026RBC CapitalOutperform—
Aug 5, 2026CitigroupNeutral—
May 15, 2026RBC CapitalOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Feb 23, 2026

Microfluidics Research Report 2026-2035: A $20.73 Billion Market by 2030 with Thermo Fisher Scientific, PerkinElmer, Dolomite, Agilent Technologies, Bio-Rad Laboratories, and Fluidigm Leading

The microfluidics market presents significant opportunities in laboratory-on-a-chip research, miniaturized diagnostics, pharmaceutical R&D, and personalized medicine. Growth drivers include advancements in IoT integration, point-of-care diagnostics, and high-throughput screening, with North America leading the expansion. Microfluidics Market Microfluidics Market Dublin, Feb. 23, 2026 (GLOBE NEWSWIRE) -- The "Microfluidics Market Report 2026" has been added to ResearchAndMarkets.com's offering. T

Yahoo · Feb 19, 2026

Bio-Rad Laboratories, Inc. (BIO) Achieves Modest Revenue Growth and Robust Free Cash Flow Growth

Bio-Rad Laboratories, Inc. (NYSE:BIO) is one of the best debt-free mid-cap stocks to buy according to hedge funds. On February 12, Bio-Rad Laboratories, Inc. (NYSE:BIO) delivered solid fourth-quarter and full-year results despite a challenging year marked by geopolitical uncertainty and continued pressure on academic research. The company delivered modest revenue growth and strong free cash […]

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By